Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Official Title

A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer


This is a Phase III, global, multicentre, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.

Trial Description

Primary Outcome:

  • DFS, Assessed Using Computed Tomography (CT)/Magnetic Resonance Imaging (MRI)/X-Ray in in Stage IB-IIIA (Intent-to-Treat [ITT]) Population
  • DFS, Assessed Using CT/MRI/X-Ray in Stage II-IIIA and PD-L1-Selected Subpopulation
Secondary Outcome:
  • Overall Survival (OS)
  • Percentage of Participants Who are Disease-Free at Year 3, Assessed Using CT/MRI/X-Ray
  • Percentage of Participants Who are Disease-Free at Year 5, Assessed Using CT/MRI/X-Ray
  • Percentage of Participants with Adverse Events
  • Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
  • Maximum Plasma Concentration (Cmax) of Atezolizumab
  • Minimum Serum Concentration (Cmin) at Steady-State of Atezolizumab

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society